Rare presentations of Swyer syndrome in a 13.5-year-old female; a case report and literature review Authors: Alireza Sadeghi, Romina Rezaei, Zahra Razavi, Amir Mohammad Salehi, Arash Dehghan Published: 2025 ABSTRACT BackgroundSwyer syndrome (SS), or 46, XY pure gonadal dysgenesis, is a rare disorder of sex development. It typically presents with primary amenorrhea and an absence of secondary sexual characteristics. However, in rare cases, patients may exhibit atypical features such as spontaneous breast development and menstruation.Case presentationThis report details the case of a 13.5-year-old female with a 46, XY karyotype, fully developed secondary sexual characteristics, and unilateral gonadoblastoma. The primary clinical symptoms included generalized hirsutism and secondary amenorrhea, occurring ten months after experiencing two menstrual periods. Physical examination revealed a phenotypic female of normal height with apparently normal external genitalia but clitoromegaly. Breast and pubic hair development were at Tanner stage five. Noteworthy features included generalized hirsutism and a deep voice. Initial laboratory investigations showed follicle-stimulating hormone (FSH) at 0.39 mIU/mL, luteinizing hormone (LH) at 0.43 mIU/mL, testosterone at 1.96 ng/mL, and estradiol at 79.54 pg/mL. An abdominal computed tomography (CT) scan detected a 12 × 10 × 10.5 cm calcified mass on the left side of the pelvis, originating from the ovaries. Surgical excision of the mass, along with a left salpingo-oophorectomy, was performed. Histopathology confirmed the mass as a gonadoblastoma. Chromosomal analysis confirmed the diagnosis of XY pure gonadal dysgenesis (Swyer syndrome).ConclusionThis case highlights the importance of comprehensive genetic testing in females presenting with amenorrhea despite fully developed secondary sexual characteristics. Background Swyer syndrome (SS), also known as 46, XY pure gonadal dysgenesis, is a rare disorder of sex development. Individuals with SS possess a 46, XY karyotype and a female phenotype, including a uterus and fallopian tubes. However, their gonads are streak and nonfunctional [1, 2]. Early diagnosis of 46, XY pure gonadal dysgenesis is crucial because patients with SS have an increased risk of developing gonadoblastoma and dysgerminoma [3, 4]. Most cases are diagnosed in adolescents presenting with delayed puberty and amenorrhea [5, 6]. Diagnosis is based on a thorough evaluation, including medical history, clinical assessment, laboratory and imaging studies, cytogenetic tests, and histological examination of the gonads. However, this diagnosis can sometimes be challenging [7, 8]. In rare instances, patients may exhibit spontaneous breast development and menstruation, which can delay diagnosis [5]. To our knowledge, ten cases of spontaneous breast development and five cases of menstruation without hormone replacement therapy have been reported in the literature. Also, due to a lack of functional gonads, virilization is not typically seen in SS individuals. therefore, germ cell tumors should be considered in those with the development of male secondary sexual characteristics (virilization) at puberty and thereafter [9]. In the current study, we present the case of a 13.5-year-old female with normal pubertal development, virilization, and secondary amenorrhea attributed to gonadoblastoma. Furthermore, we review instances of SS with atypical presentations as reported in the literature. Case report A 13.5-year-old adolescent, reared as female, presented to the pediatric endocrine outpatient clinic with a complaint of excessive generalized hair growth persisting for three years. Additionally, the patient reported secondary amenorrhea following two previous episodes of vaginal bleeding, with her last menstruation occurring eight months ago. Since then, she has not menstruated. She reported no abdominal pain or changes in bowel habits but mentioned increased sweating and appetite. The patient also noted weight gain and aggressive behaviors. She was born to a consanguineous marriage as the third child, having two healthy older brothers. She was delivered by Cesarean section at 35 + 3 weeks of gestation. Despite the pre-term delivery, her initial examinations indicated good general health, with no perinatal distress (Apgar score 10/10) and normal growth parameters (length 47 cm = 25–50th percentile, weight 2070 g, head circumference 31.5 cm). Her medical history includes hospitalization for several days during infancy due to premature birth, poor sucking, and anterior anus malposition. She has been experiencing seizures and has been under treatment with carbamazepine for the past three years. Her family history is unremarkable. During the physical examination, the patient appeared phenotypically female: weight 67 kg, height 160 cm, BMI 26, normal blood pressure, and apparently normal external genitalia, except for clitoromegaly (clitoral length: 3 cm, and width: 2 cm). Secondary sexual development was consistent with Tanner stage five for both breast and pubic hair. Aside from generalized hirsutism (modified Ferriman-Gellway score: 25/36) and a deep voice, no other pathological findings were observed. Further evaluation included routine blood work, assessment of gonadotropin and sex hormone levels, and imaging of internal genital organs. Laboratory findings revealed low follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels, elevated free testosterone levels, and normal estradiol levels according to female normal range. Serum tumor marker evaluation indicated increased levels of lactate dehydrogenase (LDH), α-fetoprotein, beta human chorionic gonadotropin (β-hCG), and inhibin B. In contrast, inhibin A and carcinoembryonic antigen (CEA) levels were within the normal range (Table 1). Table 1Laboratory test results of the hormonal profile according to female range (A) and serum tumor markers (B)A TestResultNormal rangeUnit Testosterone1.960.1–0.9ng/ml LH0.430.7–28mIU/ml FSH0.391.4–7.3mIU/L DHEA-S0.90.8–6.2µg/dL Estradiol79.5443–250pg/ml ACTH43.83Up to 50pg/ml TSH3.390.26–6mlU/LB TestResultNormal rangeUnit Inhibin A537.28–89.95pg/ml Inhibin B424.5up to 273pg/ml CEA1.46up to 6.5ng/ml Beta hCG44.73up to 10IU/L AFP7.63up to 5.5IU/ml LDH442143–370IU/L Table 1Laboratory test results of the hormonal profile according to female range (A) and serum tumor markers (B)A TestResultNormal rangeUnit Testosterone1.960.1–0.9ng/ml LH0.430.7–28mIU/ml FSH0.391.4–7.3mIU/L DHEA-S0.90.8–6.2µg/dL Estradiol79.5443–250pg/ml ACTH43.83Up to 50pg/ml TSH3.390.26–6mlU/LB TestResultNormal rangeUnit Inhibin A537.28–89.95pg/ml Inhibin B424.5up to 273pg/ml CEA1.46up to 6.5ng/ml Beta hCG44.73up to 10IU/L AFP7.63up to 5.5IU/ml LDH442143–370IU/L Laboratory test results of the hormonal profile according to female range (A) and serum tumor markers (B) An abdominal and pelvic computed tomography (CT) scan revealed a relatively large calcified mass measuring 120 × 100 × 105 mm in the upper pelvic cavity (Fig. 1). Based on the clinical presentation and CT scan findings, the initial diagnosis was a mature teratoma arising from the ovary. The patient underwent a left salpingo-oophorectomy, during which a large round mass of approximately 20 × 20 cm was resected. She had an uneventful recovery following the surgery.Fig. 1A substantial calcified mass, measuring 120 × 105 × 100 mm, is visible in the upper pelvic cavity A substantial calcified mass, measuring 120 × 105 × 100 mm, is visible in the upper pelvic cavity Histopathological examination of the excised tumor revealed a firm, round, cream-colored lesion with a smooth and intact outer surface, measuring 12 × 12 × 7 cm and weighing 603 g. The cut surface was solid and homogeneous, with foci of calcification, but showed no evidence of hemorrhage, necrosis, or cystic degeneration (Fig. 2).Fig. 2Left gonadoblastoma with multifocal dysgerminoma. The outer surface is smooth (A), and the cut surface is solid and cream-yellow with multifocal calcifications (B) Left gonadoblastoma with multifocal dysgerminoma. The outer surface is smooth (A), and the cut surface is solid and cream-yellow with multifocal calcifications (B) Histological sections revealed neoplastic tissue composed of a mixture of germ cells and sex cord-stromal cells arranged in solid sheets with round hyaline-like material interspersed, surrounded by fibroconnective septae, and accompanied by extensive calcification and ossification. The cellular composition of the tumoral sheets consisted exclusively of large polygonal or round cells with clear or eosinophilic cytoplasm and large vesicular nuclei reminiscent of germinoma cells (Fig. 3). Immunohistochemistry confirmed the diagnosis of gonadoblastoma with multifocal dysgerminoma (Table 2). Karyotyping revealed a 46 XY pattern with no detectable mosaicism.Fig. 3A Tumor nest cells (horizontal arrow) surrounded by fibrous stroma, with foci of calcification (vertical arrows). B Malignant transformation into a primitive germ cell tumor (dysgerminoma) (hematoxylin and eosin (H&E); 40x (A), 100x (B)) A Tumor nest cells (horizontal arrow) surrounded by fibrous stroma, with foci of calcification (vertical arrows). B Malignant transformation into a primitive germ cell tumor (dysgerminoma) (hematoxylin and eosin (H&E); 40x (A), 100x (B)) Table 2Immunohistochemistry test. PLAP: placental alkaline phosphatase,TestResultC-kitPatchy positivePLAPPatchy positiveCalretininPatchy positiveWT-1Focally positiveInhibinFocally and faintly positive Table 2Immunohistochemistry test. PLAP: placental alkaline phosphatase,TestResultC-kitPatchy positivePLAPPatchy positiveCalretininPatchy positiveWT-1Focally positiveInhibinFocally and faintly positive Immunohistochemistry test. PLAP: placental alkaline phosphatase, After establishing the diagnosis of SS, the patient was advised to undergo a prophylactic right salpingo-oophorectomy and to have regular follow-ups in the endocrinology clinic. However, due to unspecified reasons and a lack of family support, the patient was lost to follow-up. Discussion and conclusion SS was first described by Swyer in 1955 in two individuals with 46 XY karyotypes, female phenotypes, tall stature, female genitalia, normal müllerian structures, and primary amenorrhea [4]. The exact incidence of SS is unknown, but studies estimate that it occurs in approximately 1 in 80,000 to 1 in 100,000 children born with a female phenotype [2, 10, 11]. Approximately 70% of SS cases have an unknown etiology. However, a minority of cases are associated with pathogenic variants in key genes involved in testis determination, including SRY, SOX9, MAP3K1, and NR5A1 [12]. SS is typically diagnosed during puberty through karyotyping following hormonal evaluation for primary amenorrhea. Individuals with SS have nonfunctional gonads and typically present with primary amenorrhea and delayed puberty. The absence of estrogen secretion in SS individuals leads to elevated levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) via a negative feedback mechanism. Consequently, the hormonal profile of these patients is characterized by decreased serum levels of estradiol and increased serum levels of gonadotropins (LH and FSH) [7]. However, the clinical presentations and hormonal profile of our patient differed significantly from those of a typical SS individual. Our patient had experienced menstruation and exhibited normal breast development, assessed as Tanner Stage 5. The chief complaint was generalized hair growth on her body. Unlike typical SS individuals, her hormonal profile showed no decrease in estradiol levels, and her serum gonadotropin levels were suppressed. These atypical presentations and abnormal laboratory findings can be attributed to the presence of a hormonally active ovarian tumor. Due to the presence of intraabdominal gonads, individuals with SS are at an increased risk of neoplastic transformation and the development of tumors, including gonadoblastoma, dysgerminoma, seminoma, and choriocarcinoma [7]. Gonadoblastoma is a rare ovarian mixed tumor composed of primitive germ cells and sex cord-stromal elements. Although gonadoblastoma itself is not malignant, it has the potential to transform into a malignant form called dysgerminoma, which can be life-threatening [13]. The presence of gonadoblastoma in SS patients can complicate the diagnosis, as the tumor can induce puberty and secondary sexual characteristics through hormone secretion. Additionally, the estrogen secretion by gonadoblastoma can suppress serum gonadotropins, further obscuring the diagnosis [9]. Additionally, testosterone secretion from germ cells has been reported, which can cause hirsutism and virilization as a rare manifestation of SS [9]. Several mechanisms have been suggested to explain menstruation and breast development in SS cases. These include hormone production by streak gonads, increased peripheral conversion of androgens to estrogen, heightened tissue sensitivity to estrogen, and hormone secretion from highly active ovarian tumors, such as gonadoblastoma [5]. Çatlı et al. reported a patient with a female phenotype who presented with primary amenorrhea and was subsequently diagnosed with SS. Following the diagnosis, she experienced spontaneous menstruation and then secondary amenorrhea, accompanied by the presence of bilateral gonadoblastoma [5]. Park et al. reported a case of secondary amenorrhea and breast development in a patient with pure gonadal dysgenesis without the presence of a hormone-producing neoplasm [14]. To our knowledge, only Alam et al. have reported virilization as a manifestation of SS caused by hormone secretion from gonadoblastoma [9]. However, to date, no studies have reported the simultaneous occurrence of spontaneous breast development, menstruation, and virilization in a single individual. Since 1992, only 11 cases of SS with rare presentations have been reported in the literature. These include 10 cases of breast development, 5 cases with a history of menstruation without hormone replacement therapy, and one case of virilization. The mean age at presentation was 19.7 years. Except for 3 cases [10, 14, 15], pathological examinations in these patients revealed the presence of gonadoblastoma with or without dysgerminoma. Most patients initially presented with primary or secondary amenorrhea as their chief complaint; however, two cases [16] presented with abdominal pain and distension. Notably, virilization was not reported in any of the cases with menstruation or breast development (Table 3). Table 3Summary of case reports on rare manifestations of Swyer syndrome (SS). Cases involving the development of secondary sexual characteristics due to hormone replacement therapy are not includedAuthorCountryAgePresentationKaryotypeBreast developmentMenstruationOvarian tumorManagementChoi, 2023 [10]South Korea16Primary amenorrhea46, XYNormalPrimary amenorrheaNABilateral gonadectomy Park, 2022 [14]South Korea32Secondary amenorrhea46, XYTanner stage 5Secondary amenorrheaNoneBilateral gonadectomy and salpingectomy Morawiecka-Pietrzak, 2021 [17]Poland15Primary amenorrhea46, XYTanner stage 5Primary amenorrheaBilateral gonadoblastomaBilateral gonadectomy Alam, 2020 [9]India16Virilization46, XYAbscentPrimary amenorrheaBilateral gonadoblastomadysgerminomaBilateral gonadectomy Dural, 2019 [18]Turkey17Primary amenorrhea46, XYTanner stage 5Primary amenorrheaBilateral gonadoblastomadysgerminomaBilateral gonadectomy Çatlı, 2015 [5]Turkey15Primary amenorrhea46, XYTanner stage 5Spontaneous menstrual cyclesBilateral gonadoblastomaBilateral gonadectomyItler, 2008 [19]Turkey26Secondary amenorrhea46, XYTanner stage 4Secondary amenorrheaBilateral gonadoblastomaleft dysgerminomaBilateral gonadectomyBehtash, 2007 [16]Iran20Abdominal pain and distention46, XYTanner stage 5Primary amenorrheaRight dysgerminomaMass resection, chemotherapyBehtash, 2007 [16]Iran17Abdominal pain and distention46, XYTanner stage 4Secondary amenorrheaRight dysgerminomaUnilateral gonadectomy Tanwani, 2003 [15]United States23Primary amenorrhea, hyperthyroidism46, XYTanner stage 4Primary amenorrheaNoneBilateral gonadectomy McClure, 1992[20]Northern IrelandNASecondary amenorrhea46, XYNASecondary amenorrheaBilateral gonadoblastomadysgerminomaNAThe current study, 2024Iran13.5Virilization, secondary amenorrhea46, XYTanner stage 5Secondary amenorrheaLeft gonadoblastomaleft dysgerminomaUnilateral gonadectomy Table 3Summary of case reports on rare manifestations of Swyer syndrome (SS). Cases involving the development of secondary sexual characteristics due to hormone replacement therapy are not includedAuthorCountryAgePresentationKaryotypeBreast developmentMenstruationOvarian tumorManagementChoi, 2023 [10]South Korea16Primary amenorrhea46, XYNormalPrimary amenorrheaNABilateral gonadectomy Park, 2022 [14]South Korea32Secondary amenorrhea46, XYTanner stage 5Secondary amenorrheaNoneBilateral gonadectomy and salpingectomy Morawiecka-Pietrzak, 2021 [17]Poland15Primary amenorrhea46, XYTanner stage 5Primary amenorrheaBilateral gonadoblastomaBilateral gonadectomy Alam, 2020 [9]India16Virilization46, XYAbscentPrimary amenorrheaBilateral gonadoblastomadysgerminomaBilateral gonadectomy Dural, 2019 [18]Turkey17Primary amenorrhea46, XYTanner stage 5Primary amenorrheaBilateral gonadoblastomadysgerminomaBilateral gonadectomy Çatlı, 2015 [5]Turkey15Primary amenorrhea46, XYTanner stage 5Spontaneous menstrual cyclesBilateral gonadoblastomaBilateral gonadectomyItler, 2008 [19]Turkey26Secondary amenorrhea46, XYTanner stage 4Secondary amenorrheaBilateral gonadoblastomaleft dysgerminomaBilateral gonadectomyBehtash, 2007 [16]Iran20Abdominal pain and distention46, XYTanner stage 5Primary amenorrheaRight dysgerminomaMass resection, chemotherapyBehtash, 2007 [16]Iran17Abdominal pain and distention46, XYTanner stage 4Secondary amenorrheaRight dysgerminomaUnilateral gonadectomy Tanwani, 2003 [15]United States23Primary amenorrhea, hyperthyroidism46, XYTanner stage 4Primary amenorrheaNoneBilateral gonadectomy McClure, 1992[20]Northern IrelandNASecondary amenorrhea46, XYNASecondary amenorrheaBilateral gonadoblastomadysgerminomaNAThe current study, 2024Iran13.5Virilization, secondary amenorrhea46, XYTanner stage 5Secondary amenorrheaLeft gonadoblastomaleft dysgerminomaUnilateral gonadectomy Summary of case reports on rare manifestations of Swyer syndrome (SS). Cases involving the development of secondary sexual characteristics due to hormone replacement therapy are not included Bilateral gonadoblastoma dysgerminoma Bilateral gonadoblastoma dysgerminoma Bilateral gonadoblastoma left dysgerminoma Bilateral gonadoblastoma dysgerminoma Left gonadoblastoma left dysgerminoma Early diagnosis of SS holds significant clinical importance, not only for preventing the risk of tumor formation and malignancy but also for enabling early sex hormone treatment to ensure proper pubertal development and bone health. Once the diagnosis is confirmed, prophylactic bilateral gonadectomy should be performed as soon as possible due to the substantial risk of gonadoblastoma and dysgerminoma in SS patients. Typical pubertal development in these patients can be induced and maintained through sex hormone treatment [7]. In conclusion, individuals with SS are typically diagnosed at puberty and receive appropriate treatment. However, rare manifestations such as secondary amenorrhea and breast development can complicate the diagnosis. Our study, along with similar studies, demonstrates that the presence of developed breasts and menstruation does not exclude SS. Therefore, we recommend karyotyping all patients with primary or secondary amenorrhea to rule out SS. Our study also indicates that virilization can occur due to the hormonal activity of gonadoblastoma in advanced stages in patients with SS.